NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 856 DKK | -2.58% |
|
-0.86% | +22.52% |
| 12:11pm | Scholz promises support for pharma sector in Germany as Merck invests | RE |
| Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
Presenter SpeechLars Jørgensen (Executives)I'm Lars Fruergaard Jørgensen. I'm the CEO of Novo ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
878.7
DKK
Average target price
904.2
DKK
Spread / Average Target
+2.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.52% | 562B | |
| +25.61% | 660B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +13.51% | 219B | |
| -9.57% | 196B | |
| +6.65% | 199B | |
| -8.75% | 149B | |
| -5.21% | 146B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S, Q2 2022 Earnings Call, Aug 05, 2022
